NYSE:GWRE
NYSE:GWRESoftware

Can Guidewire (GWRE) Turn New AI Underwriting Tools Into a Durable Competitive Advantage?

In recent days, Guidewire Software and several insurance clients announced new deployments of Guidewire Cloud Platform, alongside the Olos product release introducing unified pricing tools and AI-powered underwriting and claims capabilities. Together with stronger quarterly results and higher revenue guidance, these moves highlight how Guidewire is deepening cloud adoption while expanding into higher-value analytics and AI services for insurers. We’ll now consider how Guidewire’s new Olos...
NYSE:DLR
NYSE:DLRSpecialized REITs

Should New Oracle Cloud Ties in Singapore Require Action From Digital Realty Trust (DLR) Investors?

Recently, Digital Realty announced new Oracle Cloud Infrastructure FastConnect connectivity and an Oracle Solution Center in Singapore, while reporting stronger-than-expected earnings and higher full-year guidance driven by growing AI and cloud infrastructure demand. By pairing AI-ready data center investments with enhanced cloud connectivity for major clients like Oracle in Southeast Asia, Digital Realty is reinforcing its role as a core enabler of AI and hybrid cloud workloads across its...
NYSE:FERG
NYSE:FERGTrade Distributors

Ferguson (NYSE:FERG) Valuation Check After Earnings Beat, Guidance Raise and 7% Dividend Hike

Ferguson Enterprises (FERG) just delivered a solid quarterly update, combining higher sales, fatter margins, and a 7% dividend bump. Management also nudged full year growth guidance higher, leaning on acquisitions and steady non residential demand. See our latest analysis for Ferguson Enterprises. Even with today’s 2.34% one-day share price gain to $231.32, Ferguson is still digesting a recent pullback. A 33.42% year-to-date share price return and 21.54% one-year total shareholder return show...
NYSE:DOV
NYSE:DOVMachinery

Dover (DOV) Valuation Check After Q3 Beat, Margin Strength and Upgraded Earnings Guidance

Dover (DOV) is back on investors radar after its third quarter update showed steady revenue gains, faster earnings growth, and a guidance bump that points to more confidence from management heading into year end. See our latest analysis for Dover. The upbeat third quarter has clearly shifted sentiment, with the recent earnings pop and guidance raise helping drive a 7.47% 1 month share price return and reinforcing Dover’s strong 3 year total shareholder return of 44.28% despite a modest 1 year...
NasdaqGS:AMD
NasdaqGS:AMDSemiconductor

How Investors Are Reacting To Advanced Micro Devices (AMD) Expanding Its Helios AI Data Center Platform

Earlier this month, AMD announced an expanded collaboration with Hewlett Packard Enterprise to deliver its new “Helios” rack-scale AI architecture, combining EPYC CPUs, Instinct GPUs, Pensando networking and the ROCm software stack to power large-scale AI and HPC systems, including Europe’s upcoming Herder supercomputer at HLRS in Germany. At the same time, cloud provider Vultr revealed plans for a very large global rollout of AMD Instinct-based AI infrastructure and future adoption of the...
NYSE:F
NYSE:FAuto

Is Ford (F) Still Fairly Priced After Its Recent Multi‑Month Gain?

Ford Motor (F) has quietly added to its gains, with the stock up about 2% on the day, roughly 2% over the month, and 14% in the past 3 months. See our latest analysis for Ford Motor. Zooming out, Ford’s recent rally sits on top of a solid backdrop, with the share price up strongly on a year to date basis and a five year total shareholder return approaching triple digits, suggesting momentum and confidence are still building rather than fading. If Ford’s move has you thinking about the rest of...
NYSE:BLK
NYSE:BLKCapital Markets

BlackRock (BLK): Valuation Check as New Systematic Alternatives ETF Extends Its Liquid Alts Toolkit

BlackRock (BLK) just added another piece to its ETF toolkit with the iShares Systematic Alternatives Active ETF, extending its lead in liquid alternatives as investors hunt for smoother, less market tied return streams. See our latest analysis for BlackRock. All of this product activity, from outcome focused income ETFs to liquid alternatives like IALT, comes as BlackRock’s 1 year total shareholder return of 3.78 percent lags its powerful 3 year total shareholder return of 63.68 percent. This...
NasdaqGS:ACLX
NasdaqGS:ACLXBiotechs

What Arcellx (ACLX)'s Anito‑cel Phase 2 Data Means For Shareholders

Arcellx, Inc. recently reported new positive data from its pivotal Phase 2 iMMagine-1 trial of anitocabtagene autoleucel (anito-cel) in heavily pretreated relapsed or refractory multiple myeloma, highlighting deep and durable responses with a manageable safety profile and no delayed or non-ICANS neurotoxicities observed to date. With anito-cel partnered alongside Kite, a Gilead company, and holding Fast Track, Orphan Drug, and RMAT designations, Arcellx is positioning the therapy as a...
NYSE:KMX
NYSE:KMXSpecialty Retail

Is CarMax a Bargain After a 49.3% Slide Despite Recent Share Price Rebound?

If you are wondering whether CarMax is finally priced like a bargain after its brutal slide, or if it is cheap for a reason, this article is for you. The stock has bounced 5.6% over the last week and 23.9% over the past month, but it is still down 49.3% year to date and 52.6% over the last year, a classic setup that attracts value hunters and risk takers alike. Recent headlines have focused on a tougher used car demand backdrop and shifting consumer sentiment, alongside ongoing questions...
NasdaqGS:BLLN
NasdaqGS:BLLNHealthcare

BillionToOne (BLLN) Revenue Surge Tests Bullish Growth Narrative Despite Ongoing EPS Losses

BillionToOne (BLLN) has just put another big quarter on the board, with Q3 2025 revenue at about $62.8 million and Basic EPS of roughly -$0.20, as investors gauge how fast the top line can outrun still negative earnings. The company has seen revenue move from roughly $34.5 million in early 2024 to about $41.7 million later that year and then to $62.8 million in 2025, while Basic EPS shifted from about -$0.76 to -$1.30 and then to -$0.20 over the same stretch, setting up a story where rapid...
NYSE:WELL
NYSE:WELLHealth Care REITs

Is Welltower’s (WELL) Strong Same-Store NOI Hiding a Deeper Balance Sheet Advantage?

Recent updates show that Welltower Inc. reported very large normalized FFO growth and 14.5% same-store NOI growth, supported by stronger senior housing demand, occupancy gains, and active portfolio recycling through acquisitions and dispositions. A key insight is that this performance is underpinned by low leverage and ample liquidity, which give the healthcare REIT flexibility to pursue growth while managing macroeconomic and interest rate pressures. Next, we’ll examine how this strong...
NYSE:C
NYSE:CBanks

What Citigroup (C)'s Preferred Stock Reset and Funding Moves Mean for Shareholders

In early December 2025, Citigroup Inc. redeemed all US$1.50 billions of its 4.000% Series W preferred stock and simultaneously created a new 6.625% Fixed Rate Reset Noncumulative Preferred Stock, Series HH, while continuing to issue and refinance a range of senior unsecured notes across currencies and maturities. These capital and funding moves, alongside new leadership appointments in Japan and South Korea and ongoing investor outreach, suggest Citi is actively reshaping its balance sheet...
NasdaqGS:GRAB
NasdaqGS:GRABTransportation

Grab (NasdaqGS:GRAB): Reassessing Valuation After Bullish Roadshow Update on Fintech Profitability and Growth

Grab Holdings (GRAB) just wrapped a roadshow that refocused attention on its fintech engine, with management stressing accelerated loan growth and a realistic path to segment profitability next year, alongside fresh board changes supporting execution. See our latest analysis for Grab Holdings. Despite the fintech buzz and fresh board additions, Grab’s 1 month share price return of minus 12.2 percent shows momentum has cooled, even as its 3 year total shareholder return of 56.5 percent still...
NYSE:BRK.B
NYSE:BRK.BDiversified Financial

Berkshire Hathaway (BRK.B): Taking Stock of Valuation After a Recent Pullback in Share Price

Berkshire Hathaway (BRK.B) has quietly eased off its highs, with the stock down over the past week and month even as its year to date and 3 year returns remain comfortably positive. See our latest analysis for Berkshire Hathaway. That pullback comes after a strong run, with the latest share price at $490.43 and an 8.7% year to date share price return. The 5 year total shareholder return of 121.0% still underlines how powerful the long term compounding has been. If Berkshire’s slower momentum...
NYSE:TFX
NYSE:TFXMedical Equipment

Teleflex (TFX): Reassessing Valuation After a Quiet 16% One-Month Share Price Rebound

Teleflex (TFX) has quietly climbed about 16 % over the past month after a long stretch of weak returns, drawing fresh attention from investors who are wondering whether this rebound signals a genuine shift in sentiment. See our latest analysis for Teleflex. That 16.25% 1 month share price return stands in sharp contrast to Teleflex’s weak longer term total shareholder returns, with the 5 year total shareholder return down 66.55%. This suggests the latest move looks more like early momentum...
NYSE:ABM
NYSE:ABMCommercial Services

ABM Industries (ABM): Rethinking Valuation After Recent 1-Month Share Price Rebound

ABM Industries (ABM) has quietly outperformed the broader market over the past month, with the stock climbing about 9% even as its year to date and 1 year returns remain negative. See our latest analysis for ABM Industries. That recent 1 month share price return of 8.54% to about $45.90 stands in contrast to a weaker year to date share price return and a negative 1 year total shareholder return. This suggests near term momentum is improving even as the longer term picture remains more...
NasdaqCM:CLDX
NasdaqCM:CLDXBiotechs

Should Celldex’s Global Phase 3 EMBARQ Trial for Barzolvolimab in Inducible Urticaria Require Action From CLDX Investors?

Earlier this week, Celldex Therapeutics announced it has begun a global Phase 3 EMBARQ trial of barzolvolimab in adults with cold urticaria and symptomatic dermographism who remain symptomatic despite H1 antihistamines or biologics, enrolling about 240 patients across 75 sites in 7 countries. This marks the second Phase 3 program for barzolvolimab and follows a prior placebo-controlled Phase 2 study where the drug achieved statistically significant improvements in provocation test responses...
NYSE:APO
NYSE:APODiversified Financial

Why Apollo Global Management (APO) Is Up 10.8% After $3 Billion Natural Gas Partnership Announcement

In early December 2025, Capital Power announced it had signed an MOU with Apollo Funds to pursue U.S. merchant natural gas generation acquisitions, with up to US$3.00 billion of potential equity commitments and Capital Power operating the acquired assets and earning management and performance fees. Alongside this push into large-scale energy and data-center-linked power assets, Apollo is also extending its reach in private markets through areas such as sports ownership and retirement...
NasdaqGS:AEVA
NasdaqGS:AEVAElectronic

Assessing Aeva Technologies (AEVA) Valuation After Landmark Level 3 LiDAR Supply Deal with European Automaker

Aeva Technologies (AEVA) just landed a major win, being chosen as the exclusive LiDAR supplier for a top European automaker's global Level 3 vehicle platform. This development is sparking fresh attention on the stock and its long term revenue potential. See our latest analysis for Aeva Technologies. The market has been quick to respond, with a 12.78% 7 day share price return and year to date share price gains above 200 percent signaling that sentiment and growth expectations are clearly...
NYSE:BRBR
NYSE:BRBRPersonal Products

BellRing Brands (BRBR): Valuation Check After Zacks Strong Sell Downgrade and Earnings Estimate Cut

BellRing Brands (BRBR) just landed on the Zacks Rank 5 Strong Sell list after earnings estimates were cut by about 15% over the past two months, putting fresh pressure on expectations. See our latest analysis for BellRing Brands. Even with that downgrade, the stock has bounced hard in the very short term, with a 1 month share price return of 17.79%, but that comes after a steep year to date share price decline of 55.36%. Near term momentum looks more like a sharp rebound than a decisive trend...
NYSE:NGVT
NYSE:NGVTChemicals

Has Ingevity’s 48.8% Rally in 2025 Outpaced Its Fundamental Recovery?

Wondering if Ingevity at around $58.83 is still a smart buy or if the easy money has already been made? You are not alone; this stock has quietly been drawing fresh attention from value focused investors. After a tough few years, the share price has surged, up 12.6% over the last week, 18.8% over the past month, and 48.8% year to date, even though the 3 and 5 year returns are still down 15.5% and 19.7% respectively. Part of this turnaround story reflects shifting sentiment around specialty...
NYSE:AMCR
NYSE:AMCRPackaging

Assessing Amcor (NYSE:AMCR)’s Valuation After Its Recent Share Price Decline

Amcor (AMCR) has quietly slipped about 3% over the past week and remains down roughly 12% this year, even as revenue and net income continue to grow. This sets up an interesting value debate. See our latest analysis for Amcor. At around $8.20, Amcor’s 1 year to date share price return of negative 12.3% and 1 year total shareholder return of negative 13.4% signal fading momentum, even as earnings growth nudges sentiment rather than transforms it. If you like the steady cash generation story...
NYSE:ABR
NYSE:ABRMortgage REITs

Assessing Arbor Realty Trust’s Valuation After Analyst Upgrade, Insider Buying and Q3 Dividend Hold

Analyst Upgrade Tied to Insider Buying and Q3 Dividend Hold Arbor Realty Trust (ABR) just picked up an analyst upgrade after a wave of insider buying and a mixed Q3 update that still kept its quarterly dividend steady at 0.30 dollars per share. See our latest analysis for Arbor Realty Trust. The upgrade and insider buying come against a tougher backdrop, with the share price at 9.05 dollars and a steep year to date share price return of minus 34.33 percent. At the same time, the five year...
NYSE:MMM
NYSE:MMMIndustrials

What 3M (MMM)'s Deutsche Bank Downgrade Amid Turnaround Efforts Means For Shareholders

In early December 2025, Deutsche Bank downgraded 3M from “Buy” to “Hold,” reflecting more cautious expectations for the company’s medium-term growth and aligning its outlook more closely with industrial peers. This shift in analyst sentiment comes even as 3M reports progress on its turnaround plan, including margin expansion and restructuring efforts such as the recent healthcare spin-off into Solventum. Against this backdrop of a more cautious Deutsche Bank rating, we’ll now examine how...